Abstract
Use of non-overall survival (OS) endpoints in HTA assessments is limited by the difficulty in reliably proving long-term clinical and economic benefits. Using early breast cancer (EBC; stages 1 and 2) and multiple myeloma (MM; all stages) as examples, this research aims to identify the specific actions that must be taken to ensure that non-OS endpoints are fit-for-purpose for use in reimbursement decisions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
